[2025-06-09] Neowise Biotechnology and BeOne Medicines Enter Licensing Agreement to Advance Development of Next-Generation Cell Therapies

Neowise Biotechnology announced today that it has entered into a non-exclusive licensing agreement with BeOne Medicines Ltd. Under the terms of the agreement, Neowise will grant BeOne rights to one of its proprietary antigen-specific TCR molecules for the development of next-generation, iPSC-based off-the-shelf cell therapies.

Read more

[2023-03-15] Neowise Biotechnology Secures Close to RMB 200 Million in Series A+ Financing to Accelerate TCR-T Cell Therapy Development for Solid Tumors

Neowise Biotechnology completed a Series A+ financing round of close to RMB 200 million. The round attracted investments from well-known healthcare-focused funds, including Oriza Seed Capital, Marathon Venture Partners, GEM Co., Ltd., Orange Land Capital, Zhongxin Capital, and Leader Venture Capital.

Read more

[2021-10-14] Neowise Biotechnology Completes Series A Financing

Neowise Biotechnology has completed its Series A financing round, led by TF Capital and followed by Sinopharm Capital.

Read more